erythromycin has been researched along with clinafloxacin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cassell, GH; Crabb, D; Duffy, LB; Pate, MS; Schmid, T; Waites, KB | 1 |
| Hof, H; Nichterlein, T; Walz, A | 1 |
| Cohen, MA; Huband, MD | 1 |
| Alegre-Martin, J; Odenholt, I; Petermann, W; Phillips, MJ; Tack, K; Trostmann, U; Welling, L; Willcox, PA | 1 |
1 trial(s) available for erythromycin and clinafloxacin
| Article | Year |
|---|---|
A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2001 |
8 other study(ies) available for erythromycin and clinafloxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Topics: Anti-Infective Agents; Ciprofloxacin; Clindamycin; Culture Media; Erythromycin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Tetracycline; Ureaplasma | 1991 |
Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteriological Techniques; Ciprofloxacin; Colony Count, Microbial; Erythromycin; Fluoroquinolones; Gentamicins; Legionella pneumophila; Legionnaires' Disease; Macrophages; Mice; Penicillins; Quinolones; Tumor Cells, Cultured | 1997 |
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clindamycin; Erythromycin; Fluoroquinolones; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma hominis; Mycoplasma pneumoniae; Naphthyridines; Quinolones; Tetracycline; Ureaplasma urealyticum | 1997 |